摘要
目的研讨慢性乙型肝炎患者使用恩替卡韦与干扰素进行抗病毒治疗的临床价值。方法选择我院收诊于2017年6月至2018年6月的102例慢性乙型肝炎患者作为实验对象,并随机分配患者入两组,在常规基础治疗下,Ⅰ组(n=51)接受干扰素单药治疗,Ⅱ组(n=51)同时配合恩替卡韦用药,分析评估两组的抗病毒情况。结果与Ⅰ组比较,Ⅱ组患者在HBV-DNA转阴率、HBe Ag血清学转换率及ALT复常率方面均有明显提高,有统计学意义(P<0.05)。治疗前,两组在各项肝功能指标(ALT、AST等)上的对比,无统计学意义(P> 0.05);治疗后,Ⅱ组在各项肝功能指标的测定结果上较Ⅰ组均显著改善,比较有统计学意义(P<0.05)。结论对慢性乙型肝炎患者使用恩替卡韦联合干扰素进行抗病毒治疗有确切的效果,且对患者肝功能的改善有明显帮助,值得推荐。
Objective To investigate the clinical value of anti-viral therapy with entecavir and interferon in patients with chronic hepatitis B. Methods One hundred and two patients with chronic hepatitis B admitted to our hospital from June 2017 to June 2018 were selected as subjects. Patients were randomly assigned to receive two groups. Under routine basic treatment, group I(n =51) Interferon monotherapy was given, and group Ⅱ(n =51) was combined with entecavir to analyze and evaluate the antiviral status of the two groups. Results Compared with group Ⅰ, patients in group Ⅱ had significant improvement in HBV-DNA conversion rate, HBe Ag seroconversion rate, and ALT recurrence rate, which were statistically significant(P< 0.05). Before treatment, there was no significant difference in the liver function indexes(ALT, AST, etc.) between the two groups(P> 0.05). After treatment, the results of the liver function indicators in group Ⅱ were better than those in group Ⅰ. Significant improvement, statistically significant(P< 0.05). Conclusion The use of entecavir combined with interferon for antiviral therapy in patients with chronic hepatitis B has a definite effect and is helpful for the improvement of liver function in patients. It is recommended.
作者
寇俊峰
KOU Jun-feng(Anning Hospital of Lanzhou General Hospital,Lanzhou,Gansu 730070)
出处
《智慧健康》
2018年第28期107-108,共2页
Smart Healthcare
